CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −55,000 | 0 | ||
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −17,717 | 500 | ||
| 2026-09-16 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +195,841 | $23.34 | $4.6M | 628,727 |
| 2026-09-16 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −99,716 | $63.26 | $6.3M | 529,011 |
| 2026-09-16 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −96,125 | $63.64 | $6.1M | 432,886 |
| 2026-09-16 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −195,841 | 108,493 | ||
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +350 | $17.96 | $6K | 98,547 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +55,000 | $15.46 | $850K | 153,547 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +57,500 | $26.88 | $1.5M | 211,047 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −65,104 | $63.12 | $4.1M | 145,943 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −47,746 | $63.61 | $3.0M | 98,197 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Employee stock option (right to buy) 10b5-1 | −350 | 0 | ||
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Employee stock option (right to buy) 10b5-1 | −55,000 | 0 | ||
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Employee stock option (right to buy) 10b5-1 | −57,500 | 0 | ||
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +20,000 | $17.44 | $349K | 138,016 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −27,473 | $62.00 | $1.7M | 110,543 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −20,735 | $62.61 | $1.3M | 89,808 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,900 | $63.69 | $121K | 87,908 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −400 | $65.31 | $26K | 87,508 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −20,000 | 0 |
Page 2 of 41 · 802 trades